StockData
Legend Biotech Corp logo

Legend Biotech Corp (LEGN) stock

LEGNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 20-F on Mar 10, 2026Score 3/30
$15.25−0.85 (-5.28%)

Close on Nov 20, 2026Market cap $2.82BP/E –Yield –

Legend Biotech operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Legend Biotech's operating income for the twelve months ending Jun 30, 2026 was -$55.18M. For fiscal 2025 it was -$136.50M.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$136.50M–
FY2024Dec 31, 2024-$309.50M–
FY2023Dec 31, 2023-$528.10M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$57.70M–
Q1 FY2026Mar 31, 2026-$49.80M–
Q4 FY2025Dec 31, 2025-$19.63M–
Q3 FY2025Sep 30, 2025-$43.45M–
Q2 FY2025Jun 30, 2025-$21.90M–
Q1 FY2025Mar 31, 2025-$51.70M–
Q4 FY2024Dec 31, 2024-$79.31M–
Q3 FY2024Sep 30, 2024-$70.36M–

More Legend Biotech figures

See a number that looks wrong?